{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T17:19:34Z","timestamp":1790529574750,"version":"4.1.0"},"reference-count":20,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>PrabotulinumtoxinA-xvfs (Jeuveau), a botulinum toxin type A, was approved by the Food and Drug Administration for the temporary improvement in the appearance of moderate-to-severe glabellar lines in February 2019. This article will review phase II and III clinical trials to assess the efficacy, safety, and clinical application of this novel, aesthetic-only drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>A systematic literature review was performed using the terms \u201cglabellar lines AND prabotulinumtoxinA\u201d in the PubMed database. ClinicalTrials.gov was searched to identify nonpublished studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction<\/jats:title>\n                    <jats:p>Articles written in English between November 2019 and June 2020 discussing phase II and phase III clinical trials were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis<\/jats:title>\n                    <jats:p>By the primary efficacy end point on day 30, more patients achieved a greater than 2-point improvement on the Glabellar Line Scale (GLS) at maximum frown compared with baseline on day 0. The proportions of participants who responded to treatment with prabotulinumtoxinA were 67.5% and 70.4% versus 1.2% and 1.3% in placebo groups across 2 identical clinical trials ( P &lt; 0.001). Patients receiving prabotulinumtoxinA experienced greater improvement in GLS at maximum frown on day 30 (87.2%) compared with onabotulinumtoxinA (82.8%) and placebo (4.2%; P &lt; 0.001). PrabotulinumtoxinA was well tolerated across all studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice<\/jats:title>\n                    <jats:p>This review provides a detailed analysis of the safety and efficacy of prabotulinumtoxinA-xvfs and includes special considerations to help guide patients and clinicians.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PrabotulinumtoxinA is a safe and effective new addition to the repository of available treatments for the appearance of glabellar lines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1060028020943527","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:28:30Z","timestamp":1595464110000},"page":"354-361","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["PrabotulinumtoxinA-xvfs for the Treatment of Moderate-to-Severe Glabellar Lines"],"prefix":"10.1177","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3835-6697","authenticated-orcid":false,"given":"Mary B.","family":"Gadarowski","sequence":"first","affiliation":[{"name":"Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6325-7581","authenticated-orcid":false,"given":"Rima I.","family":"Ghamrawi","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine, Winston-Salem, NC, USA"},{"name":"University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"bibr1-1060028020943527","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1989.01670200066010"},{"key":"bibr2-1060028020943527","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2009.08.001"},{"key":"bibr3-1060028020943527","first-page":"31","volume":"7","author":"Walker TJ","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"bibr4-1060028020943527","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199604)19:4<488::AID-MUS9>3.0.CO;2-8"},{"key":"bibr5-1060028020943527","doi-asserted-by":"publisher","DOI":"10.1080\/14764170260030126"},{"key":"bibr6-1060028020943527","doi-asserted-by":"publisher","DOI":"10.1097\/DSS.0000000000001903"},{"key":"bibr7-1060028020943527","unstructured":"Highlights of prescribing information: JEUVEAU (prabotulinumtoxinA-xvfs). Accessed April 25, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761085s000lbl.pdf"},{"key":"bibr8-1060028020943527","unstructured":"Faces P. What is Jeuveau and is it better than BOTOX\u00ae? Accessed June 25, 2020. https:\/\/www.facesdr.com\/what-is-jeuveau-and-can-it-beat-botox\/"},{"key":"bibr9-1060028020943527","unstructured":"Evolus Inc. BLA multi-disciplinary review and evaluation (BLA 761085) DWP-450 (JEUVEAU). Accessed April 26, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761085Orig1s000MultiR.pdf"},{"key":"bibr10-1060028020943527","unstructured":"Evolus Inc. Safety study of DWP-450 (botulinum purified neurotoxin, type A) injection to treat glabellar lines (EV-004). Accessed May 24, 2020. https:\/\/ClinicalTrials.gov\/show\/NCT02184988"},{"key":"bibr11-1060028020943527","unstructured":"Evolus Inc. Safety study of DWP-450 (botulinum toxin, type a) to treat glabellar lines\u2014EV-006 (EV-006). Accessed May 24, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02428608"},{"key":"bibr12-1060028020943527","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjz110"},{"key":"bibr13-1060028020943527","unstructured":"BOTOX. Package insert. Allergan; 2019. Accessed May 28, 2020. https:\/\/media.allergan.com\/actavis\/actavis\/media\/allergan-pdf-documents\/product-prescribing\/20190626-BOTOX-Cosmetic-Insert-72715US10-Med-Guide-v2-0MG1145.pdf"},{"key":"bibr14-1060028020943527","unstructured":"Dysport\u00ae. Package insert. Ipsen Biopharm Ltd; 2018. Accessed April 29, 2020. https:\/\/www.ipsen.com\/websites\/Ipsen_Online\/wp-content\/uploads\/sites\/9\/2019\/01\/21084019\/Dysport_Full_Prescribing_Information.pdf"},{"key":"bibr15-1060028020943527","unstructured":"Xeomin\u00ae. Package insert. Merz Pharmaceuticals; 2019. Accessed July 4, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125360s074lbl.pdf"},{"key":"bibr16-1060028020943527","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12627"},{"key":"bibr17-1060028020943527","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2013.09.009"},{"key":"bibr18-1060028020943527","unstructured":"Mishra M. FDA approves cheaper Botox rival to treat frown lines. Accessed April 28, 2020. https:\/\/reut.rs\/2S8iv9q"},{"key":"bibr19-1060028020943527","unstructured":"Hilton L. Jeuveau takes aim at aesthetic market share. Accessed April 28, 2020. https:\/\/www.dermatologytimes.com\/article\/jeuveau-takes-aim-aesthetic-market-share"},{"key":"bibr20-1060028020943527","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020943527","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020943527","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020943527","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:44Z","timestamp":1777374944000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020943527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1177\/1060028020943527"],"URL":"https:\/\/doi.org\/10.1177\/1060028020943527","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]}}}